A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

Status:
RECRUITING

Trial end date:
2028-10-01

Target enrollment:

Participant gender:

The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.

PHASE2

The Christ Hospital

pembrolizumab